Tipifarnib in Treating Patients With Myeloproliferative Disorders

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2005 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00005846
First received: June 2, 2000
Last updated: June 4, 2011
Last verified: July 2005

June 2, 2000
June 4, 2011
June 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00005846 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tipifarnib in Treating Patients With Myeloproliferative Disorders
Phase I/II Study of the Farnesyltransferase Inhibitor R115777 (NSC 702818) in Patients With Myeloproliferative Disorders

RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: This phase I/II trial is studying the side effects of tipifarnib and to see how well it works in treating patents with myeloproliferative disorders.

OBJECTIVES:

  • Determine the toxic effects of tipifarnib in adult patients with myeloproliferative disorders.
  • Determine hematological responses, including changes in WBC count and erythroid responses, in this patient population treated with this drug.
  • Determine the cytogenetic response in bone marrow of patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to prior substantive treatment (yes vs no).

Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 4 weeks for a maximum of 4 courses in the absence of unacceptable toxicity or disease progression. Patients with continued hematologic response after completion of the fourth course may receive additional courses at the discretion of the investigator.

PROJECTED ACCRUAL: A total of 25 patients (12-13 per stratum) will be accrued for this study within 25 months.

Interventional
Phase 1
Phase 2
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic/Myeloproliferative Neoplasms
Drug: tipifarnib
Not Provided
Gotlib J, Loh M, Vattikuti S, et al.: Phase I/II study of tipifarnib (ZARNESTRA, farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders(MPDs): preliminary results. [Abstract] Blood 100 (Suppl 1): 798a, 2002.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Diagnosis of chronic myelogenous leukemia (CML)

    • Philadelphia chromosome (Ph) positive OR
    • BCR-ABL positive by polymerase chain reaction
    • Must meet 1 of the following 2 conditions:

      • Chronic phase

        • Persistent or progressive disease on maximum tolerated interferon or imatinib mesylate, as evidenced by increasing WBC count, peripheral blood myeloid immaturity, progressive anemia, and/or persistence or relapse of abnormal cytogenetics and/or molecular findings
        • Interferon or imatinib mesylate intolerant
      • Accelerated phase

        • Persistent or progressive disease on imatinib mesylate
      • Patients who have not received interferon or imatinib mesylate due to allergy or refusal are eligible OR
  • Diagnosis of chronic myelomonocytic leukemia

    • Proliferative type (WBC at least 12,000/mm3)
    • Less than 5% blasts in peripheral blood and no more than 20% blasts in bone marrow OR
  • Diagnosis of undifferentiated myeloproliferative disorder OR
  • Diagnosis of atypical CML (Ph negative)
  • No blast crisis phase of CML, atypical CML, or undifferentiated myeloproliferative disorders

    • No more than 20% blasts in peripheral blood or bone marrow
  • Diagnosed more than 3 months before study entry

PATIENT CHARACTERISTICS:

Age:

  • 21 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • More than 4 months

Hematopoietic:

  • See Disease Characteristics
  • No requirement for platelet transfusion
  • No thrombocytopenia-related bleeding

Hepatic:

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST/ALT no greater than 2 times ULN

Renal:

  • Creatinine no greater than 2.0 mg/dL

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Capable of swallowing capsules
  • No other concurrent severe disease that would preclude study compliance
  • No septicemia or other severe infection
  • No iron deficiency

    • If marrow aspirate not available, transferrin saturation at least 20% and ferritin greater than 50 ng/mL
  • No other contributing causes of anemia (e.g., autoimmune or hereditary hemolytic disorders, gastrointestinal blood loss, B12 or folate deficiency, or hypothyroidism)

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics
  • At least 4 weeks since prior interferon
  • At least 4 weeks since prior hematopoietic growth factors
  • No prior allogeneic bone marrow transplantation

Chemotherapy:

  • At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas) except for hydroxyurea which may be used to manage elevated cell counts through the beginning of the second course of study therapy

Endocrine therapy:

  • No concurrent androgens
  • No concurrent corticosteroids (e.g., greater than 10 mg/day prednisone or equivalent steroid dosage) except as premedication for transfusions

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Other:

  • No other concurrent standard or investigational cytotoxic agents
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00005846
CDR0000067864, SUMC-NCI-38, NCI-38
Not Provided
Not Provided
Stanford University
National Cancer Institute (NCI)
Study Chair: Peter L. Greenberg, MD Stanford University
National Cancer Institute (NCI)
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP